I try to follow trends in ortho. Some reimbursement trends, like this one, pop up out of nowhere.
Reimbursement pressure in spine surgery has reached a breaking point.
Payers are no longer content with nibbling around the edges—they’re now directly attacking one of the most established tools in cervical fusion: the interbody biomechanical cage under CPT 22853.
By labeling these devices “experimental” despite decades of clinical use, they’re not just impacting margins; they’re challenging who gets to define the Standard of Care.
In May 2026, the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, backed by nearly every major spine society, issued a strong multi-society statement drawing a firm line against these blanket denials.
For surgeons running high-velocity practices, ASC operators, startups, distributors, and investors—this fight matters deeply. It strikes at the heart of surgical throughput, outpatient economics, and the ability to deliver modern implant technology in an efficient care model.
This isn’t some niche billing squabble—it’s a full-on turf war over who actually decides the Standard of Care in spine surgery. When payers slap “experimental” on a 2...
